Table 1.
Demographic and clinical characteristics of patients (N=743).
| Characteristics | Overall | Negative cases (n=462) | Positive cases (n=281) | P value | ||||||
| Males, n (%) | 484 (65.1) | 276 (59.7) | 208 (74.0) | <.001 | ||||||
| Agea (years), median (IQR) | 30 (25-45) | 30 (25-45) | 31 (25-44) | .62 | ||||||
| Weighta (kg), median (IQR) | 56.0 (50.0-63.0) | 55.00 (49.0-63.0) | 57.0 (51.5-63.0) | .06 | ||||||
| Education level, n (%) | .55 | |||||||||
|
|
Lower than middle school | 201 (32.2) | 123 (33.1) | 78 (30.8) |
|
|||||
|
|
Middle school | 152 (24.3) | 93 (25.0) | 59 (23.3) |
|
|||||
|
|
Bachelor’s degree or higher | 272 (43.5) | 156 (41.9) | 116 (45.8) |
|
|||||
| Incomea (RMBb), median (IQR) | 500,000 (300,000-800,000) | 500,000 (300,000-800,000) | 600,000 (500,000-1,000,000) | .002 | ||||||
| Heighta (cm), median (IQR) | 168.0 (160.0-173.0) | 167.0 (160.0-172.0) | 168.0 (162.0-173.0) | .03 | ||||||
| Hepatitis B, n (%) | 24 (3.2) | 16 (3.5) | 8 (2.8) | .81 | ||||||
| Diabetes, n (%) | 69 (9.3) | 48 (10.4) | 21 (7.5) | .23 | ||||||
| BMIa, median (IQR) | 20.0 (18.5-22.1) | 19.9 (18.4-22.0) | 20.2 (18.7-22.2) | .39 | ||||||
| Pyrazinamide dosea (g), median (IQR) | 16.8 (3.0-60.0) | 24.0 (3.1-87.9) | 5.4 (3.0-25.6) | <.001 | ||||||
| Rifampicin dosea (g), median (IQR) | 13.5 (1.3-67.5) | 40.5 (5.5-94.5) | 3.2 (1.2-12.6) | <.001 | ||||||
| Ethambutol dosea (g), median (IQR) | 18.7 (2.2-91.1) | 50.3 (4.4-139.2) | 5.3 (2.2-18.8) | <.001 | ||||||
| Isoniazid dosea (g), median (IQR) | 8.1 (0.8-37.0) | 22.8 (3.6-58.3) | 2.0 (0.6-6.5) | <.001 | ||||||
| Recent alanine transaminase measurementa,c (U/L), median (IQR) | 13.0 (10.0-23.0) | 11.0 (8.3-16.0) | 27.0 (17.0-34.0) | <.001 | ||||||
| Rate of change in alanine transaminase levelsa,d (U/[Lday]), median (IQR) | 0.0 (–0.1 to 0.1) | 0.00 (–0.1 to 0.1) | 0.27 (0.0 to 0.6) | <.001 | ||||||
aNonnormally distributed variables.
b1 RMB=US $0.15.
cPatients’ most recently determined alanine transaminase level before the latest hepatic examination.
dAverage rate of change of the patients’ last 2 alanine transaminase measures before the final liver function test (increment divided by the duration).